These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 34327561)
21. ABVD plus radiotherapy versus EVE plus radiotherapy in unfavorable stage IA and IIA Hodgkin's lymphoma: results from an Intergruppo Italiano Linfomi randomized study. Pavone V; Ricardi U; Luminari S; Gobbi P; Federico M; Baldini L; Iannitto E; Ucci G; Marcheselli L; Orsucci L; Angelucci E; Liberati M; Gavarotti P; Levis A; Ann Oncol; 2008 Apr; 19(4):763-8. PubMed ID: 18180244 [TBL] [Abstract][Full Text] [Related]
22. PET-adapted therapy after three cycles of ABVD for all stages of Hodgkin lymphoma: results of the GATLA LH-05 trial. Pavlovsky A; Fernandez I; Kurgansky N; Prates V; Zoppegno L; Negri P; Milone G; Cerutti I; Zabaljauregui S; Mariano R; Grecco HF; Basquiera AL; Saba S; Rudoy S; Sackmann F; Castano V; Remaggi G; Cabrejo M; Roveri E; Casale MF; Cabane V; Taus R; Venturini C; Sakamoto F; Varela AI; Riddick M; Pavlovsky S; Br J Haematol; 2019 Jun; 185(5):865-873. PubMed ID: 30864146 [TBL] [Abstract][Full Text] [Related]
23. Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma. Stephens DM; Li H; Schöder H; Straus DJ; Moskowitz CH; LeBlanc M; Rimsza LM; Bartlett NL; Evens AM; LaCasce AS; Barr PM; Knopp MV; Hsi ED; Leonard JP; Kahl BS; Smith SM; Friedberg JW Blood; 2019 Oct; 134(15):1238-1246. PubMed ID: 31331918 [TBL] [Abstract][Full Text] [Related]
24. ABVD followed by BV consolidation in risk-stratified patients with limited-stage Hodgkin lymphoma. Park SI; Shea TC; Olajide O; Reddy NM; Budde LE; Ghosh N; Deal AM; Noe JF; Ansell SM Blood Adv; 2020 Jun; 4(11):2548-2555. PubMed ID: 32516414 [TBL] [Abstract][Full Text] [Related]
30. Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study. Hentrich M; Berger M; Wyen C; Siehl J; Rockstroh JK; Müller M; Fätkenheuer G; Seidel E; Nickelsen M; Wolf T; Rieke A; Schürmann D; Schmidmaier R; Planker M; Alt J; Mosthaf F; Engert A; Arasteh K; Hoffmann C J Clin Oncol; 2012 Nov; 30(33):4117-23. PubMed ID: 23045592 [TBL] [Abstract][Full Text] [Related]
31. Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin's lymphoma. Avigdor A; Bulvik S; Levi I; Dann EJ; Shemtov N; Perez-Avraham G; Shimoni A; Nagler A; Ben-Bassat I; Polliack A Ann Oncol; 2010 Jan; 21(1):126-32. PubMed ID: 19608615 [TBL] [Abstract][Full Text] [Related]
32. Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials. Sasse S; Bröckelmann PJ; Goergen H; Plütschow A; Müller H; Kreissl S; Buerkle C; Borchmann S; Fuchs M; Borchmann P; Diehl V; Engert A J Clin Oncol; 2017 Jun; 35(18):1999-2007. PubMed ID: 28418763 [TBL] [Abstract][Full Text] [Related]
33. Non-growing follicle density is increased following adriamycin, bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy in the adult human ovary. McLaughlin M; Kelsey TW; Wallace WH; Anderson RA; Telfer EE Hum Reprod; 2017 Jan; 32(1):165-174. PubMed ID: 27923859 [TBL] [Abstract][Full Text] [Related]
34. Comparison of dose-dense ABVD and standard ABVD in the treatment of early unfavorable and advanced Hodgkin's lymphoma: a retrospective analysis. Tao YX; Sun SY; Kang SY; Zhou LQ; Shi YK; Li YX; Sun Y J Huazhong Univ Sci Technolog Med Sci; 2014 Apr; 34(2):260-264. PubMed ID: 24710942 [TBL] [Abstract][Full Text] [Related]
35. Phase II study of interim PET-CT-guided response-adapted therapy in advanced Hodgkin's lymphoma. Ganesan P; Rajendranath R; Kannan K; Radhakrishnan V; Ganesan TS; Udupa K; Lakshmipathy KM; Mahajan V; Sundersingh S; Rajaraman S; Krishnakumar R; Sagar TG Ann Oncol; 2015 Jun; 26(6):1170-1174. PubMed ID: 25701453 [TBL] [Abstract][Full Text] [Related]
36. The predictive role of interim PET after the first chemotherapy cycle and sequential evaluation of response to ABVD in Hodgkin's lymphoma patients-the Polish Lymphoma Research Group (PLRG) Observational Study. Zaucha JM; Malkowski B; Chauvie S; Subocz E; Tajer J; Kulikowski W; Fijolek-Warszewska A; Biggi A; Fallanca F; Kobylecka M; Dziuk M; Woszczyk D; Rybka J; Kroll-Balcerzak R; Bergesio F; Romanowicz A; Chamier-Cieminska A; Kurczab P; Giza A; Lesniewski-Kmak K; Zaucha R; Swietlik D; Wróbel T; Knopinska-Posluszny W; Walewski J; Gallamini A Ann Oncol; 2017 Dec; 28(12):3051-3057. PubMed ID: 28950332 [TBL] [Abstract][Full Text] [Related]
37. 2-deoxy-2[F-18] fluoro-D-glucose positron emission tomography Deauville scale and core-needle biopsy to determine successful management after six doxorubicin, bleomycin, vinblastine and dacarbazine cycles in advanced-stage Hodgkin lymphoma. Picardi M; Fonti R; Della Pepa R; Giordano C; Pugliese N; Nicolai E; Salvatore M; Mainolfi C; Venetucci P; Rascato MG; Cappuccio I; Mascolo M; Vigliar E; Troncone G; Del Vecchio S; Pane F Eur J Cancer; 2020 Jun; 132():85-97. PubMed ID: 32334339 [TBL] [Abstract][Full Text] [Related]
38. Post-ABVD/pre-radiotherapy (18)F-FDG-PET provides additional prognostic information for early-stage Hodgkin lymphoma: a retrospective analysis on 165 patients. Ciammella P; Filippi AR; Simontacchi G; Buglione M; Botto B; Mangoni M; Iotti C; Merli F; Marcheselli L; Bisi G; Ricardi U; Versari A Br J Radiol; 2016; 89(1061):20150983. PubMed ID: 27022777 [TBL] [Abstract][Full Text] [Related]
39. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. Gobbi PG; Levis A; Chisesi T; Broglia C; Vitolo U; Stelitano C; Pavone V; Cavanna L; Santini G; Merli F; Liberati M; Baldini L; Deliliers GL; Angelucci E; Bordonaro R; Federico M; J Clin Oncol; 2005 Dec; 23(36):9198-207. PubMed ID: 16172458 [TBL] [Abstract][Full Text] [Related]
40. Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. von Tresckow B; Plütschow A; Fuchs M; Klimm B; Markova J; Lohri A; Kral Z; Greil R; Topp MS; Meissner J; Zijlstra JM; Soekler M; Stein H; Eich HT; Mueller RP; Diehl V; Borchmann P; Engert A J Clin Oncol; 2012 Mar; 30(9):907-13. PubMed ID: 22271480 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]